Sunday, November 23, 2014

Genomic Screening


Share

My greatest interest is in the correlation of genomic information with the medical record both for diagnostic purposes and for the data mining that will be available from the resulting combined databases, both clinical and genomic.
The present overly cautious approach to bio-molecular testing -- that is testing for suspected variants on the basis of clinical suspicion -- limits the science of data mining. With this limitation, any additional abnormalities are viewed as incidental to a skewed population of suspected cases.
Studies based on massive insurance data are flawed from the beginning. Insurance diagnosis is entered according to the studies the clinician wishes to do in order to meet the diagnostic requirements for the test -- representing tentative diagnosis, a speculative or at best a differential diagnosis. Often-times the insurance clerk picks a diagnosis that approximates the physician’s but which better meets the requirements for reimbursement.
The screening of all patients -- with their permission -- on the other hand, will build a correlation between molecular and clinical findings that is more valid for research and can more cleanly contribute to a differential diagnosis and differential risk factors.
We have only scratched the surface of the information that will be forthcoming from molecular biology. We need to open the flood-gate of genomic information for clinical correlation with statistical analysis on an ongoing real-time basis. The data from multiple clinics and private practices could be combined anonymously and indefinitely in a medical school or trusted institution; its value will grow with time. It’s diagnostic and correlative legs will reinforce one another with time.
When I sold my practice/clinic there were over fifty thousand charts, a gold mine for data mining. Most old medical records are ultimately neglected or lost as were mine. This is front line data, which differs from the national or regional data collected by institutions. It is local data and as such more personal and thus more explicit and if analyzed real-time, more critical.
This process of learning as we go is the scientific method and the basis of medical science. The learning process should extend to all physicians willing to include it in their practice. I feel passionate about working in a team setting, to bring genetic screening to the medical clinic, the private practice and the community.
The goal would be the free distribution of a standalone software application that would securely store the whole genome of patients, whilst correlating it with that patient’s real-time clinical data. More relevant, however, the continuing growth in data-mining in the two matched databases will lead to new insights and certainties not otherwise rapidly achievable.
As an aside one might observe that evidence based protocols place more emphasis on treatment than on diagnosis. Missed and wrong diagnoses remain a major problem, a fact partially borne out by the US’s poor ranking in the Global Burden of Disease (GBD) studies. A byproduct of this initiative will lead to enhanced diagnostic decision support and a quantum improvement in patient care and outcome.

Tuesday, November 11, 2014

Lung-Cancer Screening with Low-Dose CT


Share | Numerous journals weighed in on the pros and cons of CT screening for lung cancer in high risk patients. The idea of a series of three CT scans seems overly expensive and an over dose of radiation considering the number of false positives. A review in the Resident e-Bulletin of the NEJM the teaching topic reports the article by M.K. Gould in the November 6th issue: NEJM, 371, 1813-1820 outlines the following.
Lung cancer has an 18% 5 year survival rate and early detection would help. The National Lung Screening Trial (NLST) consisted of 50,000 patients from 33 centers. Low-dose CT was compared with chest X-ray reporting 20% fewer deaths in the CT group, 247 vs. 309 for 2 year follow up. If valid statistically, that would be 3 deaths per 1000 saved.
The screening produced 39% positive reports, 95% of which proved false, however. The author suggested that the resulting additional CT scans and invasive procedures produced few complications: 2% from needle biopsy, 4% by bronchoscopy, and 4% from surgery. 73% of the needle biopsies and bronchoscopies were negative and 24% of the surgeries were benign. Only 1% of these invasive procedures experienced complications, 20% of whom did not have lung cancer. (approximately 0.2% complication rate for non-cancer)
Twenty years ago, our diagnostic routine (Swedish Hospital IM Denver) for 30 and more pack a day smokers with a cough was bronchoscopy, bronchial brushings, culture and chest X-ray. With the low complication rate for bronchoscopy in non malignant patients, why would one choose the overly expensive three CT screening with it's radiation exposure and 95% false positive rate when a low risk and relatively inexpensive bronchoscopy yields more definitive results? It does become a question of sensitivity, however. One would have to re-examine the claimed 20% reduction in 2 year mortality and apply the same if not better trial for the sensitivity of fiber-optic bronchoscopy and bronchial brushings in the early detection of bronchial genic carcinoma. One would be dependent on conventional PA and Lateral for the detection of  non bronchial genic CA.

Saturday, November 8, 2014

Autopsy


Share | A sign hanging over the door to the pathology lab in Paris read, "Death comes to the aid of the living." Around 1793, Marie Francois Bichat (1771-1802) moved to Paris from Lyon bringing clinical pathology to the bedside. The formalization of autopsy as part of clinical medicine catapulted the art of diagnosis and pathophysiology into a science and onto a quantum advancement in the understanding of disease and the rationality of patient care.
Today that tool, autopsy, which made American medicine the science that it became is all but lost to physicians. We still claim to be the most advanced, but the numbers say otherwise. See global burden of disease (GBD).

Sunday, November 2, 2014

Genomic Medicine


Share | The Ambrose Monell Fellowship at Cleveland Clinic suggests, importantly, that the successful fellow will understand how to form hypotheses from clinical observations and to design experiments to effectively answer the hypothesis. In essence, this appears to be the near universal role of clinical genetics, working from the clinical to the laboratory.
Arguably, the opposite might yield greater diagnostic accuracy and efficacy by correlating the genomic profile back to the signs, symptoms and anthropomorphic data of the patient. Testing for only suspected abnormalities to confirm a diagnosis, removes the chance for finding a missed diagnosis, questioning a wrong diagnosis or establishing an individual patient database from which future information might be derived.
I'm looking for a place where I can link the patient history with an inexpensive, less than $100 US, genomic profile and apply statistical analysis to the associations -- translational medicine. The predictive accuracy will build over time, but it will not build until you have the data and the data must be personal or highly regional. The data must apply to the patient or patients in question. A national database fails in that regard. A clinician who keeps good records and for the life of his or her practice, will have a database of some fifty thousand records. These numbers may be adequate for good data mining, but your patient is a statistic of N=1.

Saturday, October 4, 2014

Ebola


Share |
Comparing Ebola to past epidemics, there might be a similar evolutionary change. Taking the Plague for example, yersinia pestis found a vector in the flee, as carried by rats, and thus tended to spread along costal trade routs, if history serves us correctly, starting along the trade routs from the East. Plague was infectious, first relying on flees, then merely close contact, but evolving in a population devoid of resistance, it became pneumonic spreading with devastating consequences and speed. Later as uninfected persons became scares, the yersinia bacillus evolved back to a less virulent and less lethal form insuring greater sustainability. Today, yersinia can be found in a less virulent form among high prairie Marmots in Colorado.
The capacity to make that evolutionary change from infectious to pneumonic and back, could be through mutation or by the inherent capacity of its genome, driven by natural selection. Survival and procreation were best served by a change in virulence adapting to the availability and circumstances of the victims and the environment. An unprotected abundant population in close proximity favored virulence, whilst a more sparse target population with emerging resistance favored low virulence, prolonged illness with greater chance to spread or just lie low in a sustained reservoir.
Ebola in its present form, rapidly fatal and highly infectious in a crowded, unprotected population has little need to evolve other than the opportunity to do so. However, given its rapid spread, the crowded vulnerable population and a current strategy to enforce isolation and sanitary precautions as a means of control, one might worry about Ebola's chance of going pneumonic, thus leaping the barriers of isolation and protective sanitation to better exploit the target rich environment of a crowded and unprotected population.
I wonder what troops will accomplish in containing Ebola. We might better send doctors, and even so, containment might in itself trigger a more virulent and less containable spread. As a virus, Ebola might have within its DNA or gain by mutation the capacity to spread more like Small Pox. I think of the epidemic among the troops following WWI.

On the brighter side, a vaccine and experimental anti virus drugs appear to be in the offing.

Sunday, September 7, 2014

Hypoxia, Larry Glazer, TBM 900 KN


Share
When pilot in command is no longer in command


"Atlanta Center, TBM double 0 Kilo November, there is something wrong with my plane; request 18 thousand." -- "00 Kilo November, I can give you 24 thousand, is this an emergency?" (or something to that effect)


A fatal response. The words, "There is something wrong with my plane," above FL 30 in a single engine, single pilot aircraft is in itself an implied emergency. This may be a stretch for a controller, but FAA should have protocols in place to respond to the likelihood of hypoxia. Regulations require an oxygen mask immediately available to the pilot at these altitudes. Presumably the loss of cabin pressure was insidious and the pilot was already hypoxic when he made the call. At those altitudes the pilot has only a matter of seconds for rational behavior.
Better the controller had responded with, "Set altimeter to 10,000 feet and apply oxygen mask immediately. Emergency descent authorized. Report passing every thousand feet." Then the controller might clear the airspace and call a supervisor, but he or she can hardly feel responsible unless briefed on the insidious nature of hypoxia and have procedures in place to respond to that likelihood.
Nothing new about this, I imagine nearly every IFR pilot cringes when hearing of this unfortunate tragedy, with similar thoughts in mind. The FAA has altitude chamber experiences available in Oklahoma City, Pet Field in Colorado Springs and probably elsewhere. The instant fog of cold air and rapid loss of judgment will make you an instant believer. Holding your breath doesn't work. In fact you can't without hurting your lungs.
Additionally, anything less than a military style oxygen mask is inadequate, preferably positive pressure oxygen. Nasal oxygen is worthless. You need the rebreathing bag to keep your CO2 in functional range. With the cabin altitude creeping or exploding above 12,000 feet red lights should have been flashing all over the place. There is no time for complacency or discussion.
|

Tuesday, June 10, 2014

Type Two Diabetes and Arcus Senilis


Share The literature is full of the pros and cons of treating type two diabetes. Diagnosis remains the first step. There are probably as many undiagnosed cases of diabetes as there are of hypertension. T2D may be way down the list of multiple problems or due to limited time and other presenting complaints, not considered in a hurried clinic visit. Arcus Senilis, however, a gray ring around the outer edge of the cornea, presents a fairly reliable sign of T2D. Your skill in looking and using all of your senses when you encounter a patient, remains the most sophisticated and flexible diagnostic instrument of all. If you recall, Hippocrates diagnosed T2D by dipping his finger in the patient's urine and tasting it. One could have a full practice and a quality one at that by limiting him or herself to hypertension, lipidemia and diabetes. The diagnostic criteria for all three has been in place for over fifty years. However, the profession at large has been slow to applying that criteria to the general population. You might forgo the taste test, or try it out of curiosity.

Thursday, May 29, 2014

Bedside Teaching


Share

From my History of Medicine perspective, bedside teaching came to medical education as a major advance in teaching technique. It's what I experienced in medical school some 50 years ago and it was priceless.
In one form or another teaching at the bedside probably existed clear back to the Asclepian schools of medicine. Certainly preceptor-training took place at the bedside, but the breakthrough came with the university system of medical education wherein highly distinguished professors examined patients and taught small groups of students at the bedside.
Formal bedside teaching as we came to know it, grew to a fine art in Edinburgh with Hodgkin, Addison and Bright and later among the Irish professors: Cheyne, Corrigan, Stokes, Adams and Graves in Dublin around 1818.
Today, teaching rounds tends to be in the hall or in a conference room far removed from the patient. Confidentiality inhibits discussion in a two bed room and professors themselves no longer have the skill in dealing directly with the patient or teaching in front of the patient.
It behooves the student to force the issue, however. Get the patient's permission and then drag the professor reluctantly to the bedside. Introduce your instructor; show him or her the pathology. Tell the story and insist on comment and opinion. It should be easy to chide the professor or teaching fellow away from the conference room and once in the hall say, let's look in on this case; my patient is expecting you.
Once learned this habit of bedside teaching will serve the physician in dealing with consultants and or referring physicians -- providing a continuity of information and care at the patient's bedside.

 

Wednesday, May 28, 2014

Hypertension


Share Open CME claims 1:3 people in the US have HT but only 29% of them are aware of it. This sad state of affairs has nothing to do with guidelines, best evidence or medical education reform, it relates entirely to diagnosis. If you can't diagnosis it, you certainly can't treat it.

Taking a. BP is nor hard, but it requires a certain descipline: multiple readings, sitting and standing, documentation of body position and all readings. As long as BPs are done by machine or aid, we can count on gross errors. The machine is usually inaccurate. The aid is looking only for a normal reading. I had one aid ask me if that sounded right. If the doctor is not interested in finding elevated BP readings, he won't find them, but he will indeed if only he or she will take the time to do the pulse and BP. What better way to establish raport, intimacy and trust - not to mention build a quality practice.

Thursday, May 1, 2014

Best-Evidence


Share |

Best Evidence: The best evidence rule is a common law rule of evidence which can be traced back at least as far as the 18th century. In Omychund v Barker (1745) 1 Atk, 21, 49; Cliché, fashion, obsession, fad, trend, vogue, in thing, rage, frame, form, mold, mode, taste, device

Is evidence based medicine a fad, a current trend, a passing rage, or does it hold some breakthrough framework or mold that will results in better patient care? The word evidence-based has indeed become a cliché. If one were to view medical vogues as one would view a stock on the equities market, one would look at the word with a high degree of suspicion. By the time a company lands on the cover of Time Magazine, it’s stock loses its appeal, and it is time to get out. Evidence-based, has become the watch word for every medical or surgical endeavor. Medicine definitely embraces trends, which normally flourish for a few years until someone else comes along and disproves the thesis. There is nothing to disprove about evidence-based medicine; its name alone implies a changing proof. The problem with keeping pace with medical science, however, and distributing a convincing proof to the far flung reaches of clinical medicine presents an impossible challenge, at least in the way we deliver medical information today. The links below lead to a variety of evidence-based references both for treatment and for diagnosis. The last one, notably a $66 paperback has a publication date of 2009.

The problem is not the evidence; it is a problem of access, timeliness and adequacy, not to mention relevance. Medicine is a fast evolving science. A clinician, despite all claims to the contrary, is a scientist who must pyramid clinical knowledge in order to access the Information needed for her individual patient. Evidence-based medicine is a pyramid of carefully filtered information which comes to a peak somewhere far away only to be published and discriminated at a price in a branching fashion to the intended clinician. By the time the information makes it to the clinician, it is no longer timely and it is based on a question that most closely resembles the question the clinician is asking for just one individual patient. Furthermore, the evidence is based on a statistical population far removed geographically, and besides the patient is a statistic of N1 who may fall anywhere in or outside of the evidence-based parameters. The patient, furthermore, possesses a unique molecular-biological profile that is most relevant to his or her condition. The accumulation of evidence-based information has no way to relate to this patient as an individual. There is no way that standardized care, guidelines or algorithms can keep pace with bio-molecular medicine. The complexity is far too vast and the growth in knowledge is far too fast.

So, let’s get beyond the fad of evidence-based and get on with the problem of delivering current medical knowledge to the clinician regarding the individual patient. The challenge is great. We must make that information easily accessible, free and unlimited to the clinician. The patient information too must be as complete as possible, and as inexpensive as possible. There is no way to do this in an industrial free market framework. Medical Information should replace best-evidence. The information should be free to all physicians and their patients, emanate from the universities and medical schools, and linked to the individual patient’s clinical and molecular profile.

Wednesday, April 30, 2014

GPI, Genuine Progress Indicator

Share |
http://genuineprogress.net/genuine-progress-indicator/
In an attempt to give a more accurate indication of the economic health of an economy, economists have proposed the GPI which starts out with the GDP and adds environmental and human factors. Even this greatly improved metric still lacks the human factor of health. It would serve well to add the global burden of disease (GBD) ranking to the GPI in order to understand the extent to which the US falls behind economically. Health is an intrical part to the economic equation.

Saturday, April 19, 2014

What They Don't Tell You in Medical School


Share
Disease is arguably defined as a maladaptation to the environment. Given this concept, one might consider the environment as well as the patient in looking for a diagnosis -- the other side of the coin, if you will.
The environment offers many challenges: social, employment, nutrition, substance abuse, chemical toxins, packaged food additives, the pneumoconiosis, air pollution, parasitic hazards, pollens, geographic locations and even the weather and the seasons. Hippocrates did a better job of considering the environment than we do.
This week's Case 12-2014 from The Mass General Hospital famously illustrates this concept -- A 59 yr old man with fatigue, abdominal pain, anemia and abnormal liver function; Friedman, Simmons et al NEJM 2014; 370: 1542-1550 http://www.nejm.org/doi/full/10.1056/NEJMcpc1314242?query=TOC http://consortiumlibrary.org/services/ill/.
This one is worth pursuing. Read the abstract and do your own differential. Then read the case and the CPC. (sorry no autopsy) Note the number of times this patient was sent home before he was finally admitted. The pre-admission scenario may reflect the emphases increasingly placed on rapid turnover and treatment by protocol ("best evidence") without adequate diagnosis or recognition that you do not yet have one. 

Friday, April 11, 2014

Burwell


Share | Burwell's greatest asset may be a W. Virginia origin. Certainly Harvard and Oxford are impressive along with Gates and Clinton.
There may be no way to make it otherwise, but leading us out of the mess we are in as a medical profession, requires both clinical savvy, macro economics, vast clinical experience and leadership. Without vast clinical experience, I see no way to fathom the cause of the medical problems or to address the dismal ranking of US medicine in the (GBD) global burden of disease.
Disincentives, built into nearly all past bureaucratic efforts to control cost, stifle progress at nearly every turn.. Privatization, incorporation, insurance and standardization opens the purse strings -- the feeding trough, if you will -- to greed, exploitation and a welcome mat for any and all new gimmicks, technologies, drugs and procedures with a price tag set by the producer.
Never mind the shiny new hospitals that are not even clean inside, have only fractional bed occupancy but discharge patients before it is safe -- all due to the profit motive. Medicine is not a business. It is not a free market; it requires science, dedication and humanity beyond the capacity of most outsiders.
But given all of that, I wish Burwell good luck. I wish I could say more..  

Sunday, March 23, 2014

Global Burden of Disease, TB, Malaria, HIV


Share |
Tuberculosis
Two billion carriers, one out of three world population
8.6 million new cases per year with increasing emergence of resistance
1.3 million deaths per year


Malaria
Two hundred and seven million carriers
2.7illion new cases per year
627,000 deaths per year (much reduced recent years due to Gates and others)


HIV
Thirty five million three hundred thousand carriers
2.3 million new cases per year
1.6 million deaths per year (320,000 due to TB as terminal event)
WHO 2011
Nature, Outlook Vaccines 507, 6 Mar 2014, 7490, S1-21

Sunday, February 23, 2014

Global Burden of Disease Study (GBD)

Share |

JAMA published a seminal investigation documenting the Health of America compared to other developed countries broken down by disease, risk factors, morbidity and mortality. The massive undertaking involved hundreds of collaborators in thirty-four countries and some highly sophisticated statistics comparing the burden of disease, disability and risk factors. The report here includes the developed countries participating in the Organization for Economic Co-operation and Development.  The State of US Health, 1990-2010, Burden of Disease, Injuries and Risk Factors appears in the August 14 issue of JAMA.[1] If you have any interest in the shortcomings of our health care system or the health of US’s vital human resource, this landmark document is worth the study.

Harvey Fienberg’s editorial on page 585 observes the decline in the US standing among developed nations.  Herein, “results for the United States are presented in detail for the first time.”  The statistics utilized in the study were extremely complex and all inclusive. However, Fienberg points that socioeconomic status relates strongly with mortality[2] and that socioeconomics was not included as a risk factor in this study. The collaborators agreed. The difficulty was in equating socioeconomics across the many cultures in the thirty-four nations that took part in this study.  Fienberg further observes that the assessment for the US as a whole does not account for significant regional differences. However, he does suggest that the framework for assessing the burden of disease is scalable and applicable to states, counties and municipalities.[3]
The statistical terms used in this study include:  Years of Life Lost (YLL) due to premature mortality, Years Lived with Disability (YLD), Disability Adjusted Life Years (DALY), which combines YLL and YLD and, Healthy Life Expectancy (HALE). The article compares these attributes in the thirty-four countries between 1990 and 2010. This monumental study goes beyond all previous reports by including risk factors for disease.

The diseases causing premature mortality, YLL, differed dramatically from those causing morbidity and disability, YLD. In 2010 in the US the big eight YLL were in order: Ischemic heart disease, lung cancer, stroke, COPD, road injury, self-harm, diabetes and cirrhosis. In sharp contrast, the first eight YLD were:  Low back pain, major depression, other musculo-skeletal, neck pain, anxiety disorder, COPD, disorders resulting from drug use, and diabetes.

The risk factors underlying the leading causes for both YLL and YLD diseases were almost the same. The list of risk factors included: Dietary, tobacco, HBP, high BMI, physical inactivity, high serum glucose, ambient particulate pollution, alcohol, drug use and high cholesterol. Dietary risks accounted for over 650 thousand deaths while tobacco use and hypertension accounted for some 450 thousand deaths. Obesity followed closely behind as insurance actuaries have long established. Dietary risks are by far the greatest, but tobacco, obesity, high BP, high blood glucose, sedentary life style, alcohol, cholesterol, drug abuse and air pollution follow in descending parabolic order as causes of disability.

The figure 4 illustration on page 604 in the journal and below reflects the US’s low YLL ranking compared with the thirty three other countries. The cross-index lists countries on one axis and diseases on the other with the ranking for each in the cross-index. The US is 7th from the bottom following the Check Republic and Chile in overall ranking. Our ranking by the raw longevity score, infant mortality and perinatal mortality reported elsewhere[4] are even worse.[5] The US comes in 38th in both longevity and infant mortality. The perinatal mortality rates are even worse.[6]

 Figure 4.

Rank of Age-Standardized YLL Rates Relative to the 34 OECD Countries in 2010
Numbers in cells indicate the ranks of each country for each cause, with 1 representing the best-performing country. Countries are sorted on the basis of age-standardized all-cause years of life lost (YLLs) for 2010. Diseases and injuries contributing to YLLs are ordered by the difference between the US rate and the lowest rate in the Organization for Economic Co-operation and Development (OECD) countries for each cause. Colors indicate whether the age-standardized YLL rate for the country is significantly lower (green), indistinguishable (yellow), or higher (red) from the mean age-standardized YLL rate across the OECD countries. HIV indicates human immunodeficiency virus.[7]

Fienberg writes that setting us on a healthier course will require leadership at all levels of government engaging the profession and the public. Indeed it will, but there has to be more. Fienberg mentions social economic status as a risk factor.  One might add the environmental and behavioral factors and look more closely to the dietary risk that jumps out as, not only the leading risk factor, but by a large margin. Poverty and relative poverty may play as important role as nutrition. The prevalence of ischemic heart disease, diabetes, hypertension and stroke implicate diet and obesity as the underlying cause. These too may reflect poverty as the major risk factor. However, looking at chronic kidney disease(CKD) poisoning, cirrhosis, congenital anomalies, pre-term birth problems, the cancers and the neurological, one wonders if there might not be environmental factors present in the US that are not present in the other countries. Staring at fig 4, one notices a divergence between countries that is hard to attribute to genomics, behavior or health care as outlined.

Studying this somewhat overwhelming research should not be limited to government and public health leaders etc. but may be a lesson in diagnosis itself. A medical history without a social, behavioral, environmental and psychological risk assessment will miss many of the causes of and early diagnosis of disease. One must distinguish between a problem and a diagnosis. Look for a primary underlying cause. “Peal away the layers of the onion.” Fienberg urges inquiry at both the social and biological levels. I love his quote, “Trying to understand the causation of disease using only one of these lines of research is like trying to clap with one hand.” Furthermore, we need to study the burden of disease on a smaller scale. It would be fruitful to analyze the burden of disease on a state, county and municipal level. Risk factors may vary by municipality and indeed by individual. Just as Hippocrates tasted the urine, examined every bodily orifice; he considered the weather the environment and nutrition. We too must consider, social, economic, environmental, behavioral, psychological, dietary and genomic attributes -- critical knowledge for the physician diagnostician. 

One might take exception to vague final diagnoses such as cardiomyopathy, chronic kidney disease, lower respiratory infection, community acquired pneumonia etc. One should  look at the specific cause whether a specific organism or a specific exposure. If disease is by definition a maladaptation to the environment, then one must pay as much attention to the environment as to one’s patient. The same must apply to the social and behavioral factors. Asclepian physicians paid great head to the environment, the air, the winds, the weather, the dampness and the water. Great physicians of the past, like Sherlock Homes saw things in the surroundings that others did not. Look again at figure 4. Some of the US rankings are hard to explain by today’s medical knowledge. Why do we have such excellent medical education and such sad outcomes?  Hippocrates prescribed diets in detail. Perhaps our front line clinics should provide a nutritionist as part of the team.

Food additives in the US have become a poison.  Studies clearly show the deleterious effects of pesticides, sodium, sugars etc. Anything remotely addictive added to packaged food products enhances sales but at the expense of consumer health. The lassie-fair food regulatory policies in the US differ strikingly from those in European countries where fresh foods dominate in the markets over packaged foods. Like grandmother said, eat your vegetables! However, you had better wash them first.
Poverty is an unlisted risk factor and may account for some of the dietary problems. Depletion of living standards for the entire middle class may also lead to dietary and other self-abusive behaviors. The sequestration of wealth --as in the dark ages -- may add to the behavioral risks as well. Herman Boerhaave U. of Lyden and French  Academy of Science 1728 said, “The poor are my best patients because God pays for them.” That sentiment may be hard to find in today’s busy practices. The Affordable Care Act at least establishes a principal of health as a critical infrastructure for us all. The perpetuation of insurance, fee for service and administrative burden may fall short of expectations. The European models of health care are more egalitarian. The medical schools represent our only source for the more equitable distribution of health care. University medical schools have a long history of means testing and free care in support of the poor and the medical community, but they are limited in number and distances between. Today fee for service and insurance mandates silence much of the egality that was once universal in medical schools  It would be naive to think that economics and politics are not risk factors.

We have made great strides in reducing smoking, but one has only to look to see the obesity epidemic. Drug use remains an embarrassment, and environmental pollution is still with us -- perhaps more of a problem here than in Europe.  These factors too may account for some of the discrepancies in outcome between the US and Europe.

Accessibility to care, mal distribution of physicians, the licensing of or exemption of fringe-providers, and continuity of care also play a role in our unfavorable outcomes. We are improving but at a retarded pace and at incredible cost. Diagnosis suffers also from the recent trend – all but eliminating autopsies. In the past, autopsy -- the single one thing historically that propelled us forward in scientific and medical knowledge -- has gone out of style. The CT scan is no substitute. Marie Francois Bichat, 1793, brought pathology to the bedside correlating autopsy with clinical observation. The sign over the door to his autopsy room in Paris read, “Death comes to the aid of the living” and indeed it did for two hundred years. There is no substitute for the Clinical Pathologic Conference (CPC). Even the NEJM today presents cases today without autopsy.
If you don’t do a rectal, you don’t use a head mirror, you don’t feel a pulse and you don’t look at the feet, or take off the shirt to examine the chest, then your diagnosis and your outcome will be as limited as your investment in the patient. These are but some of the shortcuts that characterize today’s “industrialized medicine.” When we practice medicine as a business, it is more profitable to skim the diagnostic caldron for high priced procedures, high patient volume and cover the missed and wrong diagnosis with liability insurance and silence. By industrializing medicine we have opened the door for any and all business ventures to feed at the health care trough no matter how marginal or how harmful.  By denying local medical societies the control over professional privileges and professional behavior, we have left the legislature valorized by lobbyists in control of behavior and the hospital, insurance and drug company free reign.

All the great doctors in history had three things in common: they traveled widely to medical centers all over the world, they translated Hippocrates and they had the Gout. I could do without the gout but would add attendance and participation in CPCs. It is time that we visited the successful healthcare systems in Europe and the East to see what works. Instead of revising curriculum by invention, visit the medical schools in other countries, much older than our own and examine their methods. We were leaders in health care for only a brief span of history, mainly during WWI and WWII while 45 years of Cold War brought both the US and Russia the four horsemen of the Apocalypse.  Perhaps it is time for another Flexner Report -- now a hundred years later.



[1] JAMA,2013;310(6):591-608. Doi:10.1001/jama.2013.13805
[2] National Research Council; Institute of Medicine. US Health in International Perspective: Shorter Lives Poorer Health. National Academies Press; 2013
[3] Katz B. Bradley J. the Metropolitan Revolution. Brookings Institution; 2013
[4]  http://www.enagic.com/enagic_life.php
[5] http://data.worldbank.org/indicator/SP.DYN.IMRT.IN
[6] http://whqlibdoc.who.int/publications/2006/9241563206_eng.pdf
[7] Figure 4 reproduced with permission JAMA RightsLink and Copyright Clearance Center Aug 14 JAMA, Christopher Murray et al; Copyright © 2013, American Medical Association